JOJose Daniel Restrepo Orozco

Jose Daniel Restrepo Orozco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jose Daniel Restrepo Orozco has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multimodal Artificial Intelligence for Prostate Cancer Diagnosis and Risk Stratification: A Scoping Review (Preprint)

    by Jesus Alejandro Alzate-Grisales, Felipe Ocampo Osorio, Jose Daniel Restrepo Orozco, Juan Diego Rendon Tabares, Miguel Perán-Teruel, Azahar Navarro Beltrán, Clara Ruiz Torres, Francisco García-García, Reinel Tabares-Soto, Juan M García-Gómez, et al.

    BACKGROUND Multimodal artificial intelligence (AI) may improve clinically significant prostate cancer (csPCa) detection and risk stratification by integrating imaging, histopathology, molecular, radiomic, and structured clinical data. OBJECTIVE This scoping review mapped recent evidence on multimodal AI for prostate cancer diagnosis, staging, prognosis, and treatment personalisation, with emphasis on data modalities, fusion strategies, validation, reproducibility, and clinical translation. METHODS A PRISMA-ScR-guided search of IEEE Xplore, Scopus, Web of Science, PubMed, and SpringerLink identified English-language peer-reviewed studies published from January 2021 to December 2025. Eligible studies applied AI to at least two data sources for prostate cancer detection, grading, staging, prognosis, recurrence prediction, or treatment selection. Two reviewers screened records and charted clinical task, modalities, fusion strategy, validation design, performance, and reproducibility indicators. RESULTS Twenty-six studies were included. Clinical variables were incorporated in 24 studies, multiparametric magnetic resonance imaging in 18, and whole-slide histopathology in six. Multimodal models usually outperformed unimodal baselines in paired comparisons, including PI-CAI performance above the median radiologist AUROC (0.91 vs 0.86) and trimodal PET/MRI/clinical models reporting AUC values up to 0.955. Evidence was limited by retrospective designs, small cohorts, geographic concentration, scarce public code, inconsistent calibration reporting, and no prospective workflow validation. CONCLUSIONS Multimodal AI is promising for biopsy triage, grading, staging, prognostication, and treatment selection, but current evidence supports research prioritisation rather than routine deployment. Prospective, diverse, transparent, and clinically embedded validation is required before multimodal AI can guide routine prostate cancer decisions.

  • Open Access

    From Data Fusion to Decision Support in Prostate Cancer: Evidence Mapping of Multimodal Artificial Intelligence for Diagnosis, Prognosis, and Treatment Selection

    by Jesús Alejandro Alzate-Grisales, Felipe Ocampo-Osorio, Jose Daniel Restrepo Orozco, Juan Diego Rendon Tabares, Miguel Perán-Teruel, Azahar Navarro Beltrán, Clara Ruiz Torres, Francisco García-García, Reinel Tabares-Soto, Juan M García-Gómez, et al.

    Artificial intelligence systems for prostate cancer are increasingly moving beyond single-source image analysis toward models that combine radiology, clinical variables, pathology, molecular measurements, and radiomics. We conducted a PRISMA-ScR-guided evidence map of peer-reviewed English-language studies published from January 2021 to December 2025 and indexed in IEEE Xplore, Scopus, Web of Science, PubMed, or SpringerLink. Eligible studies used AI or machine learning to integrate at least two information sources for prostate cancer detection, grading, staging, prognosis, recurrence prediction, or treatment selection. Two reviewers screened records and extracted study design, clinical task, input modalities, fusion approach, validation strategy, performance, reproducibility, and implementation-relevant reporting. Twenty-six studies met eligibility criteria. Clinical variables were the most frequent non-imaging input (24/26), mpMRI was the dominant imaging source (18/26), and six studies incorporated whole-slide histopathology. Reported paired comparisons usually favoured multimodal approaches, with examples including PI-CAI performance above the median radiologist AUROC (0.91 vs. 0.86) and PET/MRI/clinical models reporting AUC values up to 0.955. However, the evidence remains mostly retrospective, geographically concentrated, weakly reproducible, and rarely calibrated; none of the included studies tested a multimodal AI system prospectively inside a clinical pathway. Current findings support continued development and rigorous evaluation rather than routine deployment. The next phase of research should prioritise prospective pathway studies, diverse external validation, transparent reporting, missing-modality robustness, and patient-centred outcomes.